Piedmont Investment Advisors LLC Increases Position in Amedisys Inc (AMED)

Piedmont Investment Advisors LLC boosted its stake in Amedisys Inc (NASDAQ:AMED) by 286.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,422 shares of the health services provider’s stock after acquiring an additional 17,368 shares during the period. Piedmont Investment Advisors LLC owned about 0.07% of Amedisys worth $1,311,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Federated Investors Inc. PA lifted its position in Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after acquiring an additional 44 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Amedisys by 0.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock valued at $1,235,000 after acquiring an additional 93 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in Amedisys by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,590 shares of the health services provider’s stock valued at $414,000 after acquiring an additional 220 shares during the last quarter. Suntrust Banks Inc. lifted its position in Amedisys by 4.3% in the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock valued at $358,000 after acquiring an additional 237 shares during the last quarter. Finally, Texas Permanent School Fund lifted its position in Amedisys by 1.2% in the second quarter. Texas Permanent School Fund now owns 20,439 shares of the health services provider’s stock valued at $1,284,000 after acquiring an additional 243 shares during the last quarter. 94.47% of the stock is owned by hedge funds and other institutional investors.

Shares of Amedisys Inc (NASDAQ AMED) opened at $55.31 on Friday. Amedisys Inc has a 1-year low of $41.98 and a 1-year high of $65.91. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. The company has a market cap of $1,861.43, a PE ratio of 26.24, a PEG ratio of 1.33 and a beta of 0.70.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business had revenue of $380.20 million during the quarter, compared to analysts’ expectations of $384.59 million. During the same period in the prior year, the company earned $0.36 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. sell-side analysts anticipate that Amedisys Inc will post 2.23 EPS for the current fiscal year.

AMED has been the subject of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a report on Tuesday, November 21st. SunTrust Banks reaffirmed a “buy” rating and issued a $70.00 target price on shares of Amedisys in a report on Friday, November 10th. Robert W. Baird upped their target price on shares of Amedisys from $50.00 to $60.00 and gave the company a “neutral” rating in a report on Friday, November 10th. Craig Hallum reaffirmed a “buy” rating and issued a $68.00 target price (up from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $62.00 target price (up from $56.00) on shares of Amedisys in a report on Thursday, November 9th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $61.00.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/12/16/piedmont-investment-advisors-llc-increases-position-in-amedisys-inc-amed.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply